OCA
CTKB icon

Octagon Capital Advisors’s Cytek Biosciences CTKB Stock Holding History

Octagon Capital Advisors’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-400,000
Closed -$6.53M – 27
2021
Q4 		$6.53M Sell
400,000
-100,000
-20% -$2.09M 1.27% 18
2021
Q3 		$10.7M Buy
+500,000
New +$11.8M 2.64% 13

Other funds holding CTKB

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MGM
Miura Global Management New York $25.2M AUM 60.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Octagon Capital Advisors's CTKB Position: Q1 2022 in Review

Octagon Capital Advisors sold out of Cytek Biosciences (CTKB) in Q1 2022, closing a stake of 400,000 shares — an estimated $6.53M sold.

Octagon Capital Advisors first reported a position in CTKB in Q3 2021 and held it in 2 quarters. The position peaked at $10.7M in Q3 2021. 74 funds tracked by Wall St. Rank hold CTKB as of Q1 2022.

  • Octagon Capital Advisors reported no remaining Cytek Biosciences position as of Q1 2022 after selling out during the quarter.
  • Octagon Capital Advisors sold 400,000 Cytek Biosciences shares in Q1 2022, an estimated $6.53M.
  • Octagon Capital Advisors first reported a position in Cytek Biosciences in Q3 2021 and held it in 2 quarters.
  • Octagon Capital Advisors's Cytek Biosciences position peaked at $10.7M in Q3 2021.
  • 74 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2022.

Based on Octagon Capital Advisors's 13F filing for Q1 2022, filed 16 May 2022.